EyeCyte has secured seed funding from Pfizer to drive the development of therapeutics for diabetic retinopathy. The company is collaborating with Pfizer's Bioinnovation and io therapeutics Center and The Scripps Research Institute to develop innovative treatments for retinal diseases. EyeCyte's investors include Pfizer Venture Investments and Pfizer Strategic Investments.